Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice

Fig. 1

Trimeric form of SARS-CoV-2 RBD (T-RBD) and the self-assembled ferritin nanoparticle form of SARS-CoV-2 RBD (TF-RBD). a Schematics of the T-RBD and TF-RBD designs. The RBD (R391-D541) of the SARS-CoV-2 spike (S) protein containing the N-terminal tPA signal peptide (SP) and the C-terminal foldon (FD) trimer tag or linked to ferritin (N96 mutation; increase protein secretion) gene sequences of Helicobacter pylori was synthesized in a DNA plasmid by codon optimization. The modified mRNA was synthesized by the in vitro transcription (IVT) of a linearized DNA plasmid. b The expression of the T-RBD protein in the whole-cell lysate (WCL) and supernatant was analyzed by western blot. c, d Western blot profiles of T-RBD protein expression under reduced and nonreduced conditions. e The expression of the TF-RBD protein in the WCLs and concentrated supernatant was analyzed by western blot. f, g Western blot profiles of TF-RBD protein expression under reduced and nonreduced conditions. h Transmission electron microscopy (TEM) images showing nanoparticles formed by TF-RBD expressed in the supernatant of HEK293T cells (scale bar, 100 nm)

Back to article page